Compare Eli Lilly And Co (LLY) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Procter & Gamble Co — how do they compare? Eli Lilly And Co trades at $1,177.77 (market cap $1.04T), while Procter & Gamble Co trades at $151.2 (market cap $349.77B). The key difference: Eli Lilly And Co is far larger — about 3× Procter & Gamble Co's market cap, and Procter & Gamble Co pays the higher dividend (2.89%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Procter & Gamble Co for 131 Days on average.
| LLY | PG | |
|---|---|---|
Market Cap | $1.04T | $349.77B |
Volume | 3,064,878 | 10,055,825 |
Sector | Health | Consumer Staples |
52-Week High | $1.28K | $167.18 |
52-Week Low | $799.57 | $138.10 |
Typical Hold Time | 93 Days | 131 Days |
Enterprise Value | $1.09T | $375.61B |
Dividend Yield | 0.59% | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
Procter & Gamble (PG) trades at $151.23, up 2.31% with strong technical momentum above key support levels. The company demonstrates robust fundamentals with $84.28B revenue, 18.44% net margin, and consistent earnings beats. Recent partnership with the WNBA and supply chain enhancements support growth. Technical indicators show bullish moving averages while RSI remains neutral.
PG offers stable dividend income with 69-year growth history and trades near consensus target of $160.13. Premium valuation metrics present near-term risk if growth moderates. Strong cash flow generation and institutional support provide downside protection amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
